Purpose: This study aimed to assess the association between pretreatment c-Met overexpression in local-regional advanced cervical cancer patients treated definitively with concurrent chemoradiation therapy (CRT) and treatment outcomes including overall survival (OS), progression-free survival (PFS), distant metastases (DM) control, and local-regional control (LC).
C ervical cancer is a major cause of morbidity and mortality worldwide, with an estimated 529,800 newly diagnosed cases and 275,100 deaths in 2011. In the United States alone, it is estimated that there will 12,360 new cases in 2014. 1, 2 Definitive concurrent chemoradiation therapy (CRT) is the standard of care for treatment of patients with local-regionally advanced cervical cancer. [3] [4] [5] [6] [7] [8] [9] However, almost all patients who develop recurrence still have a poor prognosis, despite advancements in salvage treatment. [10] [11] [12] Identification of molecular biomarkers predictive of higher relapse risk after CRT is lacking. If patients who are likely to recur could be better identified then more individualized treatments could be of great benefit to this subset. Potential molecular markers would be helpful for determining prognosis and potentially for development of individualized target therapies. 11, 12 The c-Met oncogene plays an important role in cancer growth and metastasis, as well as development of drug resistance to targeted biological therapies. [13] [14] [15] [16] [17] [18] [19] [20] Baykal et al 14 reported c-Met overexpression in 60% of early-stage cervical cancer patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB disease treated primarily with surgery. Other studies reported c-Met gene overexpression in up to 11% of patients with lung cancer, 15 10% of gastric cancers, 16 and 4% of endometrial and esophageal cancers. 17, 18 This study aimed to assess the association between pretreatment c-Met overexpression in local-regional advanced cervical cancer patients (treated definitively with CRT) and treatment outcomes including overall survival (OS), progression-free survival (PFS), distant metastases (DM) control, and local-regional control (LC).
PATIENTS AND METHODS
The Institutional Review Board approved this retrospective study. The study aimed to evaluate the incidence and impact of c-Met oncogene expression on the treatment outcomes of local-regional advanced cervical cancer treated consecutively and definitively with CRT. Charts were reviewed of patients with local-regionally advanced cervical cancer who presented to our department between January 1983 and December 2009. Patients were treated with definitive cisplatinbased chemotherapy and external-beam radiation therapy (EBRT) followed by a low-dose-rate (LDR) brachytherapy boost (BT). Inclusion criteria included (1) a histologically proven diagnosis of cervical cancer stages IB1 through IVA locally advanced cervical carcinoma; (2) Eastern Cooperative Oncology Group Performance status 0 to 2; and (3) age older than 18 years. Women were excluded if treated with up-front surgery followed by adjuvant radiotherapy or CRT and also if they had prior radiotherapy for gynecologic or gastrointestinal diseases. The chart review yielded 129 eligible cervical cancer patients. Of the eligible patients, 28 had tissue available from the pathology core facility. All 28 eligible patients were treated from 2001 to 2008 utilizing the same radiation therapy technique.
All patients had a cervical biopsy with pathologic confirmation of cervical carcinoma and underwent appropriate staging work-up. Concurrent cisplatin-based EBRT was to a total dose of 45 Gy, in 1.8 Gy/fraction, 5 fractions per week for a total of 5 weeks. Parametrial boost and nodal boosts were added at the treating physician's discretion. As part of the definitive management, LDR Fletcher-Suit tandem and ovoid BT implant(s) were performed with Cs-137 sources, in 1 or 2 implants. The dose was prescribed according to the Manchester System with dose prescribed to point A based on patient and tumor characteristics. Doses to point B and the rectal and vaginal doses were also calculated. The brachytherapy treatment duration ranged from 40 to 70 hours, during which time the patients were admitted to the hospital. The details of pretreatment evaluation, treatment technique, and treatment parameters of the entire cohort of 129 patients were described in detail in an earlier report. 8 For the 28 patients for whom cervical cancer tissue was available, we calculated treatment outcomes including OS, PFS, LC, and DC. Outcomes were also stratified by c-Met overexpression as well as other relevant tumor characteristics.
Immunohistochemistry c-Met (clone C-28) immunohistochemistry was performed on formalin-fixed paraffin tissue microarray sections using the Dako EnVision polymer refine detection horseradish peroxidase (HRP) (Dako, K4002) method. Four-micron-thick sections of tissue microarray blocks (2-mm tissue cores were prepared from tumor and normal ectocervical tissue) were transferred to charged slides, deparaffinized and rehydrated before antigen retrieval in citrate buffer (pH 6) at 951C for 20 minutes. Immunohistochemistry staining was performed by use of the c-Met (rabbit polyclonal, clone C-28) antibody (diluted 1:50) (catalog No. sc-161-R; Santa Cruz Biotechnology, Santa Cruz, CA). Negative control sections were treated similarly, except the primary antibody was omitted. HRP-conjugated polymer anti-rabbit secondary (EnVision System HRP-labeled polymer; Dako, Agilent Technologies, Santa Clara, CA) was used to detect the primary antibody and 3,3 0 -diaminobenzidine was used as the chromogenic substrates. Counterstaining was performed using Meyer's hematoxylin.
Evaluation of cytoplasmic immunoreactivity for c-Met was performed and scored semiquantitatively by 3 pathologists (S.E.A., V.P., J.-J.W.), and incorporated both the intensity and percentage of immunoreactivity in invasive carcinoma (H score). 21 The immunointensity was defined as negative (0), weak (1 +), moderate (2 +), and strong (3 +) (Fig. 1) . The H score consisted of a sum of combination of immunoreactivity for intensity multiplied by percentages. The possible range of the H score was 0 to 300. A score of 30 was used as a cut off value for positive staining based on the evaluating pathologist's recommendation and was verified by a receiver-operating characteristic curve showing sensitivity and specificity of 71% and 57%, respectively, for H score of 30 (Fig. 2) . The average H score between the 3 investigators was used for statistical analysis. All pathologists were blinded to the treatment outcomes.
Statistical Analysis
Continuous variables were summarized by means, SDs, medians, and ranges. Categorical variables were summarized by frequencies and percentages. OS, PFS, LC, and DC rates were obtained via the Kaplan-Meier method and differences between groups were evaluated by the log-rank test. Hazard ratios (HRs) associated with these rates were obtained via Cox regression for both univariate and multivariate analyses.
RESULTS
The mean patient age in this cohort was 51 ± 10 years. A total of 53.57% of the patients had FIGO stage IIB disease. Almost two thirds of the patient had clinical node-negative disease. Most of the patients (78.57%) had locally advanced disease (sizeZ4 cm) at presentation. Detailed patients and tumor characteristics are presented in Table 1 . Table 2 shows total radiation therapy dose delivered to points A and B, stratified by FIGO stage. Ten patients (35.7%) had c-Met H index of >30 and 18 patients (64.3%) had c-Met H index of r30. Tables 3 and 4 Table 3 show a significant association between c-Met overexpression (H index >30) and worse 3-and 5-year OS (P = 0.003), PFS (P = 0.002), LC (P = 0.01), and DC (P = 0.0003). The log-rank test demonstrated a significant association between smoking and OS (P = 0.04), PFS (P = 0.02), LC (P = 0.047), and DC (P = 0.03). HRs and CIs obtained from the proportional hazard model for comparing cMet >30 versus c-Met <30 is presented in Table 3 . Patients with a Met H score index >30 had a HR of 6.297 for the risk of death, 5.782 for risk of disease progression, 6.28 for risk of local recurrence, and 18.173 for risk of DM compared with those with Met H index r30. There was also a significant association between OS and tumor stage (P = 0.03), as well as treatment breaks ( > 3 d throughout the treatment course) (P = 0.04) as shown in Table 4 . In addition, there was a significant association between PFS and tumor stage (P = 0.01), tumor size (P = 0.052), and treatment breaks (0.051). A multivariate analysis model that included age, FIGO stage, race, pretreatment anemia, treatment breaks, and body mass index, demonstrated that c-Met >30 significantly impacted LC (HR = 8.792, P = 0.047), and had a trend to impact OS (HR = 5.95, P = 0.08), and DM (HR = 79.749, P = 0.07). FIGO stages III and IV significantly impacted OS (HR = 25.781, P = 0.02), PFS (HR = 18.713, P = 0.02), and DM (HR = 250.412, P = 0.02).
Treatment Outcomes

DISCUSSION
This study of 28 cervical cancer patients treated definitively with CRT followed by a boost with LDR BT demonstrated a strong association between c-Met overexpression (H score index >30) and poor OS, PFS, LC, and DC. Baykal et al 14 reported that c-Met oncogene overexpression was an important parameter for disease progression, recurrence, and survival in FIGO stage IB uterine cervix cancer patients who were treated primarily with surgery. This study provides further evidence that c-Met overexpression not only impacts treatment outcomes for FIGO stage IB cervical cancer treated by surgery (Baykal and colleagues' study), but also affects overall prognosis and treatment outcomes in advanced cervical cancer patients treated with definitive CRT. In the setting of local-regional advanced cervical cancer, image-guided brachytherapy after EBRT is becoming more widely used. Results of MRI-based image-guided brachytherapy have demonstrated improved local control while minimizing treatment-induced adverse events. However, there still needs to be definitive clinical evidence of superior survival advantage compared with conventional 2-dimensional historical planning. 9, 22 Overall, treatment endpoints continue to be significantly worse in the setting of locally recurrent and metastatic cervical cancer. With a median OS up to 13 months, outcomes in these patients remain very poor. This is despite numerous clinical trials investigating different chemotherapeutic regimens before the era of individualized molecular medicine. Currently, targeted therapies aiming to knock-down specific molecular targets have emerged as an important therapeutic approach that allow tailoring treatment toward the applicable patient on an individual level with an ultimate goal of better treatment outcomes. 12, 23, 24 The Gynecologic Oncology Group (GOG) and the Radiation Therapy Oncology Group (RTOG)-now part of NRG Oncology Group-as well as various other groups have recognized the importance of identifying novel molecular therapeutic agents targeting specific pathways to improve the treatment outcomes in both the local-regional advanced and recurrent/metastatic settings. However, the majority of these studies have utilized bevacizumab in an attempt to interrupt angiogenesis with translation to a survival advantage. This potential target was reported in considerable number of reports including GOG Protocol 227-C, 25 and recently in RTOG 0417, 26 GOG 240. 12 The GOG 240 study, reported by Tewari and colleagues, randomized 452 advanced cervical cancer patients to standard chemotherapy with or without bevacizumab at a dose of 15 mg/kg. Chemotherapy consisted of cisplatin 50 mg/m 2 , plus paclitaxel at 135 or 175 mg/ m 2 or topotecan at 0.75 mg/m 2 on days 1 to 3, plus paclitaxel 175 mg/m 2 on day 1 utilizing a 2-by-2 factorial design. The study did not show superiority of topotecan-paclitaxel over cisplatinpaclitaxel (HR for death, 1.20). However, the addition of bevacizumab to chemotherapy was associated with increased OS (17.0 vs. 13.3 mo; HR for death, 0.71; 98% CI, 0.54-0.95; P = 0.004 per a 1-sided test) and higher response rates (48% vs. 36%, P = 0.008). Bevacizumab resulted in higher incidence of treatment-induced hypertension Zgrade 2 (25% vs. 2%), thromboembolic events Zgrade 3 (8% vs. 1%), and gastrointestinal fistulas Zgrade 3 (3% vs. 0%). The authors concluded that the addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer was associated with an improvement of 3.7 months in median OS. 12 On the basis of this, the FDA approved bevacizumab to treat patients with persistent, recurrent, or late-stage (metastatic) cervical cancer on August 14, 2014. Although there is a growing body of evidence that targeting angiogenesis using bevacizumab might play an important role in optimizing treatment outcomes, identifying other molecular targets in different pathways in cervical carcinogenesis might add to therapeutic options and help improve treatment outcomes. c-Met has been of increasing interest both as a predictive and prognostic biomarker in various tumor sites. [14] [15] [16] [17] [18] [27] [28] [29] [30] [31] [32] [33] Hepatocyte growth factor, which is a plasminogen-like protein that was considered a humoral mediator of liver regeneration, has been shown to be the c-Met proto-oncogene product. 13, 34 Pennacchietti et al 35 studied various in vitro cell lines including cervical cancer to find that hypoxia promotes tumor invasion by sensitizing cells to hepatocyte growth factor stimulation, which explains the molecular basis of c-Met overexpression. The authors reported that hypoxia activates transcription of the cMet proto-oncogene, and because the hypoxic areas of tumors overexpress c-Met, inhibition of c-Met expression prevents hypoxia-induced invasive cancer growth. Leo et al 27 investigated the expression of c-Met in cervical cancers in relation to intratumoral hypoxia levels and to clinicopathologic parameters, finding that although c-Met has been shown to be hypoxiainduced in vitro, it is not the mediator of deleterious effects of hypoxia for clinical outcome in cervical cancer. Cabozantinib, which is a tyrosine kinase inhibitor that targets the c-Met, VEGFR2, and RET pathways, was approved by the FDA on November 29, 2012 for the treatment of medullary thyroid cancer based on a phase III, international, multicenter, randomized, double-blind clinical trial (the EXAM study). 36 The drug is currently being examined for efficacy in other solid tumors including breast cancer, castration-prostate cancer, renal cell carcinoma, hepatocellular carcinoma, gastric or gastroesophageal junction cancer, melanoma, small cell lung cancer, ovarian cancer, and primary peritoneal or fallopian tube carcinoma. 37 Interestingly, it was shown that Met gene amplification is one of the most relevant mechanisms involved in epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) acquired resistance. Engelman et al 20 correlated the resistance to EGFR-TKI agents in lung cancers to the focal amplification of the c-Met protooncogene, and proved that inhibition of c-Met signaling in these cancer cells restored their sensitivity to EGFR-TKI. c-Met amplification was detected in 4 of 18 (22%) lung cancer specimens that had developed resistance to EGFR-TKI. They concluded that amplification of c-Met causes EGFR-TKI resistance by driving ERBB3 (HER3)-dependent activation of PI3K, and therefore, c-Met amplification may promote drug resistance in other ERBB-driven cancers as well. 20 In a study by Bean et al, 19 c-Met amplification was found in 21% of lung cancer patients with acquired resistance to EGFR-TKI and only in 3% of untreated patients, confirming that c-Met could be a relevant therapeutic target for individuals with acquired resistance to EGFR-TKIs.
Would novel molecular therapy that targets both angiogenesis through VEGFR2 and c-Met oncogene add benefit to local-regional advanced, recurrent, and/or metastatic cervical cancer patients? The answer to this question requires further controlled clinical trials to assess both the safety and efficacy 
